Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SARS-CoV-2 recombinant protein vaccines with AS03 in adults
2020-003370-41Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of SARS-CoV-2 recombinant protein vaccine monovalent D614 + AS03 adjuvant in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Sanofi. Started Nov 2020; status: completed.
02
Drugs
SARS-CoV-2 recombinant protein vaccine monovalent D614 + AS03 adjuvant
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003370-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003370-41.